ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Novel topical treatment for dysgeusia/ageusia: a case series report.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of dysgeusia has received limited study despite the significant impact taste has upon general health, nutrition, and quality of life. Taste sensation is initiated at the receptor level, leading to signal transduction and transmission to central taste centers. We assessed the potential of a topical approach to dysgeusia management.
methodsWe report retrospective results of topical application of memantine, gabapentin, and monosodium glutamate (MSG) in a group of 13 patients diagnosed with dysgeusia. Compounded lozenges containing gabapentin 10 mg, memantine 2 mg, and MSG 20 mg in a base of pectin and flavoring were dissolved in the mouth three times daily. Patient-reported changes in gustation were collected. No adverse events were reported.
resultsEleven patients (85%) reported improved taste that suggests efficacy of the lozenge in improving taste function with local topical application in people that had persisting taste loss despite prior treatment trials.
conclusionsThese findings support the potential of topical intervention for taste management that may have implications in preventive management and intervention for patients with dysgeusia/ageusia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.